This Bayesian meta-analysis combined data from 13 eligible studies to evaluate talimogene laherparepvec and other engineered viral vector immunotherapies for patients with advanced melanoma. The researchers focused on objective response rates, progression-free survival, overall survival, and treatment-related adverse events. The analysis supports complementary rather than competing roles for these therapies within current treatment paradigms.
The study found an objective response rate of 49% for TIL therapy and a median progression-free survival of 7.2 months. Overall survival was estimated at 25.8 months. A pooled estimate for objective response rate across the Bayesian synthesis was 37.8%. Sensitivity analysis excluding one specific study yielded a similar result of 38.3%.
Certainty of evidence for objective response rate was moderate. However, survival and safety outcomes were downgraded due to heterogeneity, sparse reporting, and inconsistent endpoint definitions. The study did not report specific serious adverse events or discontinuation rates. Readers should view these results as supportive of the therapy's role alongside other options, noting that survival and safety data remain less certain.